Abstract
Design and synthesis of novel 4-phenyl-1-arylsulfonylimidazolones3 and 4-phenyl-3-arylsulfonylimidazolones4 and evaluation of their cytotoxic activity against eleven human cancer cell lines and two murine leukemia cell linesin vitro were performed. As a result, a series of 4-phenyl-1(N)-arylsulfonylimidazolones (3) has been found to be the potential anticancer agent. Compounds3b, 3c, and3d exhibit strong activity as indicated by their IC50 values 0.39, 3.19, 0.31 μg/mL against A549 and 0.80, 0.48, 0.0007 μg/mL against SK-Mel-2, respectively. These compounds also possess much more potent activity (10–1000 times) than LY186641 against eleven other cell lines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References Cited
Everitt, E. and Wohlfart, C., Spectrophotometric quantitation of anchorage-dependent cell numbers extraction of naphthol blue-black-stained cellular protein.Anal. Biochem., 162(1), 122–9 (1987).
Hainsworth, J. D., Handle, K. R., Satterlee, W. G., Kuttesch, J., Johnson, D. H., Grindey, G. B., Jackson, L. E. and Greco, F. A., Phase I clinical study of N-[(4-chlorophenylamino)]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641).Cancer Res., 49, 5217–5220 (1989).
Howbert, J. J., Sulofenur.Drugs Future., 16, 517–520 1991.
Grindey, G. B., Boder, G. B., Grossman, C. S., Howbert, J. J., Poore, G. A., Shaw, W. H., Todd, G. C. and Worzalla, J. F., Further development of diarylsulfonylureas as novel anticancer drugs.Proc. Am. Assoc. Cancer Res., 28, 309 (1987).
Grindey, G. B., Identification of diarysulfonylureas as novel anticancer drugs.Proc. Am. Assoc. Cancer Res., 29, 535 (1988).
Grindey, G. B., Current status of cancer drug development: Failure or limited success.Cancer Cells, 2, 163–171 (1990).
Houghton, P. J., Hougton, J. A., Myers, L., Cheshire, P., Howbert, J. J. and Grindey, G. B., Evaluation of N-(5-indanylsulfonyl)-N′-(-chlorophenyl)urea against xenografts ofPediatric Rhabdomyosarcoma.Cancer Chemother. Pharmacol. 25, 84–88 (1989).
Houghton, P. J., Bailey, F. C., Germain, G. S., Grindey, G. B., Witt, B. C. and Houghton, J. A., N-(5-indanylsulfonyl)-N′-(4-chlorophenyl)urea, A novel agent equally cytotoxic to nonproliferating human colon adenosarcoma cells.Cancer Res., 50, 318–322 (1990).
Houghton, P. J., Bailey, F. C., Houghton, J. A., Murti, K. G., Howbert, J. J. and Grindey, G. B., Evidence for mitochondrial localization of N-(4-Methylphenylsulfonyl)-N′-(4-chlorophenyl)urea in human colon adenosarcoma cells.Cancer Res. 50, 664–668 (1990).
Jung, S. H., Song, J. S., Lee, H. S., Choi, S. U. and Lee, C. O., Synthesis and evaluation of cytotoxic activity of novel arylsulfonylimidazolidinones.Bioorg. Med. Chem. Lett. 6, 2553–2558 (1996): preliminary account of this subject was described as a communication in this reference.
Jung, S. H. and Kohn, H., Stereoselective synthesis of vicinal diamines from alkenes and cyanamide.J. Amer. Chem. Soc. 107, 2931–2943 (1985).
Kamthan, A., Scarffe, J. H., Walling, J., Hatty, S., Peters, B., Coleman, R. and Smyth, J. F., A phase II study of solufenur(LY186641) in gastric cancer.Anti-cancer Drugs, 3, 331–335 (1992).
Kang, Y. K. and Kim, D. W., Conformational studies of sulfonylurea Herbicide: Bensulfuron methyl and Metsulfuron methyl.Bull. Korean Chem. Soc., 11, 144 (1990).
Munshi, N. C., Seitz, D. E., Fosella, F., Lippman, S. N., and Einhorn, L. H., Phase II study of sulofenur(LY 186641). A novel antineoplastic agent in advanced non-small lung cancer.Proc. Am. Assoc. Cancer Res., 32, 189 (1991).
Perrin, D. D., Armarego, W. L. F. and Perrin, D. R.,Purification of laboratory chemicals, 2nd edition. Pergamon Press, Oxford, England, 1982.
Schultz, R. M., Merriman, R. L., Toth, J. E., Zimmermann, J. E., Hertel, L. W., Andis, S. L., Dudley, D. E., Rutherford, P. G., Tanzer, L. R. and Grindey, G. B., Evaluation of new anticancer agents against the MIA Paca-2 and PANC-1 human pancreatic carcinoma xenografts.Oncol. Res., 5, 223 (1993).
Scudiero, D. A., Shoemaker, R. H., Paull, K. D., Monks, A., Tierney, S., Nofziger, T. M., Seniff, D. and Boyd, M. R., Evaluation of a soluble tetrazoliun/formazan assay for cell growth: a sensitivity in culture using human and other tumor cell line.Cancer Res., 48, 4827–4833 (1988).
Skehon, P., Storeng, R., Scudiero, D. A., Monks, A., McMahon, J., Vista, D. T., Warren, J. T., Kenny, S. and Boyd, M. R., New Colorimetric cytotoxicity assay for anticancer drug screening. J. Natl. Cancer Inst., 82, 1107–1112 (1990).
Talbot, D. C., Smith, I. E., Nicolson, M. C., Powles, T. J., Button, D. and Walling, J., Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer.J. Cancer Chemother. Pharmacol., 31, 419–422 (1993).
Taylor, C. W., Alberts, D. S., Ketcham, M. A., Satterlee, W. G., Holdsworth, M. T., Plazia, P. M., Peng, Y. M., Mccloskey, T. M., Roe, D. J., Hamilton, M. and Salmaon, S. E., Clinical pharmacology of a novel diarylsulfonylurea anticancer agent.J. Clin. Oncol., 7, 1733–1740 (1989).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jung, SH., Song, JS., Lee, HS. et al. Synthesis and evaluation of cytotoxicity of novel arylsulfonylimidazolidinones containing sulfonylurea pharmacophore. Arch. Pharm. Res. 19, 570–580 (1996). https://doi.org/10.1007/BF02986031
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02986031